DNTH — Dianthus Therapeutics, Inc. stock price, charts and financials
QT57Dianthus Therapeutics, Inc.Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
101.12
-1.37-1.34%
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -2.88 | Insider Own | 14.12% | Shs Outstand | 55.93M | Perf Week | -2.09% |
| Market Cap | 5.66B | Forward P/E | - | EPS next Y | -4.57 | Insider Trans | -5.84% | Shs Float | 46.93M | Perf Month | -12.48% |
| Enterprise Value | 4.77B | PEG | - | EPS next Q | -0.94 | Inst Own | - | Short Float | 17.96% | Perf Quarter | 23.48% |
| Income | -101.00M | P/S | - | EPS this Y | -31.61% | Inst Trans | - | Short Ratio | 8.07 | Perf Half Y | 28.23% |
| Sales | 6.00M | P/B | 4.83 | EPS next Y | -20.63% | ROA | -2.47% | Short Interest | 8.43M | Perf YTD | 145.38% |
| Book/sh | 20.95 | P/C | 6.38 | EPS next 5Y | - | ROE | -3.51% | 52W High | 117.88 -14.22% | Perf Year | 169.87% |
| Cash/sh | 15.86 | P/FCF | - | EPS past 3/5Y | - | ROIC | -18.47% | 52W Low | 32.22 213.84% | Perf 3Y | 819.27% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -30.66% - | Gross Margin | 96.01% | Volatility | 4.50% 4.33% | Perf 5Y | -0.47% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | -12.94% | Oper. Margin | -11441.39% | ATR (14) | 5.08 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 26.10 | Sales Y/Y TTM | 0.00% | Profit Margin | -1570.85% | RSI (14) | 40.19 | Recom | 1.91 |
| Dividend Gr. 3/5Y | - | Current Ratio | 26.10 | EPS Q/Q | -2.27% | SMA20 | -5.81% | Beta | 1.30 | Target Price | 126.83 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -5.38% | Rel Volume | 1.21 | Prev Close | 102.49 |
| Employees | 92 | LT Debt/Eq | 0.00 | Earnings | Nov 05 | SMA200 | 28.82% | Avg Volume | 939.56K | Price | 101.12 |
| IPO Date | Jun 21, 2018 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -6.35% 156.07% | Net Debt/EBITDA | 3.70 | Volume | 1,140,314 | Change | -1.34% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-06-26 | Reiterated | HC Wainwright & Co. | Buy | $130 → $158 |
| Aug-05-26 | Reiterated | Raymond James | Strong Buy | $125 → $131 |
| Aug-05-26 | Reiterated | Wedbush | Outperform | $55 → $122 |
| Jun-10-26 | Reiterated | Jefferies | Buy | $110 → $132 |
| May-11-26 | Reiterated | Evercore ISI | $122 → $120 | |
| May-06-26 | Reiterated | Raymond James | Strong Buy | $123 → $125 |
| Apr-08-26 | Initiated | Wolfe Research | Outperform | $98 |
| Mar-10-26 | Upgrade | Raymond James | Outperform → Strong Buy | |
| Mar-09-26 | Reiterated | UBS | $81 → $98 | |
| Mar-09-26 | Reiterated | Jefferies | Buy | $51 → $98 |
Latest News· Times ET
Sep-11-26
Sep-11-2604:29AM
Sep-09-26
Sep-09-2602:57PM
Sep-04-26
Sep-02-26
Sep-02-2601:00PM
Sep-01-26
Sep-01-2604:00AM
Aug-31-26
Aug-31-2611:58PM
Aug-24-26
Aug-10-26
Aug-10-2612:07PM
Aug-09-26
Aug-09-2612:46AM
Aug-06-26
Aug-06-2607:55AM
12:03AM
Aug-04-26
12:01PM
03:00AM
Aug-03-26
Aug-03-2602:00PM
Company
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targets plasmacytoid dendritic cell (pDC) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 6 | 2 | 6 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 6 | 2 | 6 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 27 | 34 | 25 | — | — | — | — | — | — | |
| Research and Development | 97 | 146 | 83 | — | — | — | — | — | — | |
| Other Operating Expense | -1 | 0 | 0 | — | — | — | — | — | — | |
| Operating Income | -117 | -178 | -102 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 17 | 16 | 17 | — | — | — | — | — | — | |
| Net Income Before Taxes | -101 | -162 | -85 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -101 | -162 | -85 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -101 | -162 | -85 | — | — | — | — | — | — | |
| Net Income | -101 | -162 | -85 | — | — | — | — | — | — | |
| EPS (Recurring) | -2.88 | -4.20 | -2.55 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.88 | -4.20 | -2.55 | — | — | — | — | — | — | |
| EPS (Diluted) | -2.88 | -4.20 | -2.55 | — | — | — | — | — | — | |
| EBITDA | -99 | -162 | -85 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 606.72 | 782.99 | 119.90 | — | — | — | — | — | — | |
| Gross Margin | 100.00 | 100.00 | 100.00 | — | — | — | — | — | — | |
| Operating Margin | -1,950.00 | -8,900.00 | -1,700.00 | — | — | — | — | — | — | |
| Net Margin | -1,683.33 | -8,100.00 | -1,416.67 | — | — | — | — | — | — | |
| Shares Outstanding | 36 | 38 | 33 | — | — | — | — | — | — | |
| Market Capitalization | 3,640 | 1,566 | 719 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Randhawa Simrat | EVP, Head of R&D | Sep 01 '26 | Option Exercise | 20.63 | 23,124 | 477,047 | 27,124 | Sep 03 |
| Randhawa Simrat | EVP, Head of R&D | Sep 01 '26 | Sale | 106.41 | 23,124 | 2,460,691 | 4,000 | Sep 03 |
| Read Simon | Director | Aug 19 '26 | Option Exercise | 18.36 | 2,778 | 51,004 | 2,778 | Aug 19 |
| Read Simon | Director | Aug 19 '26 | Sale | 117.55 | 2,778 | 326,554 | 0 | Aug 19 |
| Veness Adam M | SVP, General Counsel and Sec. | Aug 13 '26 | Option Exercise | 18.17 | 15,000 | 272,550 | 15,000 | Aug 14 |
| Read Simon | Director | Aug 10 '26 | Sale | 109.55 | 2,777 | 304,232 | 0 | Aug 11 |
| Veness Adam M | SVP, General Counsel and Sec. | Aug 10 '26 | Option Exercise | 17.88 | 16,167 | 289,066 | 16,167 | Aug 11 |
| McGeorge Anne | Director | Aug 10 '26 | Option Exercise | 12.52 | 7,750 | 97,000 | 7,750 | Aug 11 |
| McGeorge Anne | Director | Aug 10 '26 | Sale | 109.01 | 7,750 | 844,822 | 0 | Aug 11 |
| Read Simon | Director | Aug 10 '26 | Option Exercise | 18.36 | 2,777 | 50,986 | 2,777 | Aug 11 |
| Veness Adam M | SVP, General Counsel and Sec. | Aug 10 '26 | Sale | 110.38 | 16,167 | 1,784,513 | 0 | Aug 11 |
| Veness Adam M | SVP, General Counsel and Sec. | Aug 07 '26 | Sale | 110.70 | 3,833 | 424,319 | 0 | Aug 11 |
| Veness Adam M | SVP, General Counsel and Sec. | Aug 07 '26 | Option Exercise | 17.88 | 3,833 | 68,534 | 3,833 | Aug 11 |
| Garcia Marino | CEO AND PRESIDENT | Aug 07 '26 | Option Exercise | 8.44 | 166,000 | 1,401,040 | 231,292 | Aug 07 |
| Garcia Marino | CEO AND PRESIDENT | Aug 07 '26 | Sale | 108.11 | 166,000 | 17,945,450 | 65,292 | Aug 07 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.